Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have received a consensus rating of “Buy” from the nine brokerages that are covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $39.86.

A number of analysts have recently issued reports on the company. Wedbush reaffirmed an “outperform” rating and issued a $40.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Wolfe Research initiated coverage on shares of Oruka Therapeutics in a research note on Tuesday, February 4th. They set an “outperform” rating and a $20.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, February 7th.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds have recently modified their holdings of ORKA. The Manufacturers Life Insurance Company purchased a new stake in Oruka Therapeutics in the third quarter valued at $1,037,000. Wellington Management Group LLP acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter worth about $2,013,000. Franklin Resources Inc. purchased a new stake in Oruka Therapeutics in the 3rd quarter valued at about $17,661,000. Point72 Asset Management L.P. acquired a new position in Oruka Therapeutics in the third quarter valued at about $11,822,000. Finally, RTW Investments LP purchased a new position in Oruka Therapeutics during the third quarter worth about $45,359,000. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Trading Down 2.2 %

ORKA stock opened at $11.18 on Friday. Oruka Therapeutics has a 12-month low of $10.61 and a 12-month high of $53.88. The business has a 50-day moving average price of $16.78. The firm has a market cap of $391.30 million, a PE ratio of -1.79 and a beta of 0.77.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.